Equipping Potent Cells with Validated Tumor Targeting
Chimeric antigen receptor (CAR) technology is a well-established approach to augment immune cells to fight cancer. CARs are receptors engineered to recognize specific tumor markers and can be genetically introduced to immune cells, such as NK cells or T cells. This equips these cells to recognize and engage tumor cells that possess the particular relevant marker. CAR based therapies have previously demonstrated potential benefits in the treatment of hematological malignancies.
Enhancing Potent Cell Lines with CAR-Directed Targeting